Anti-Fn14 antibody-conjugated nanoparticles display membrane TWEAK-like agonism
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Pharmaceutics (2021) 13:7, 1072. https://doi.org/10.3390/pharmaceutics13071072
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2022
- Urheber
-
Aido, Ahmed
Zaitseva, Olena
Wajant, Harald
Buzgo, Matej
Simaite, Aiva
- DOI
-
10.3390/pharmaceutics13071072
- URN
-
urn:nbn:de:bvb:20-opus-242710
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aido, Ahmed
- Zaitseva, Olena
- Wajant, Harald
- Buzgo, Matej
- Simaite, Aiva
- Universität Würzburg
Entstanden
- 2022
Ähnliche Objekte (12)
Development of Modified polylysine based antibody conjugated nanoparticles with tumor-restricted, FcγR-independent stimulatory activity by targeting Fn14
Molecular mode of action of TRAIL receptor agonists—common principles and their translational exploitation
Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
The importance of antibody isotype and idiotype in FcγR-dependent agonism induced by anti-CD40 antibodies
Development of self-adjusting cytokine neutralizer cells as a closed-loop delivery system of anti-inflammatory biologicals
Enhancement of Toll-like receptor3 (TLR3)-induced death signaling by TNF-like weak inducer of apoptosis (TWEAK)
CD40-restringierte Aktivierung der TRAIL-Todesrezeptoren durch bifunktionelle rekombinante Proteine
Generierung und Charakterisierung rekombinanter TNF-Liganden
Development of CD40-targeted bifunctional scFv-TRAIL fusion proteins that induce TRAILR1- and TRAILR2-specifc cell death and dendritic cells activation
CD70-abhängige und spezifische Aktivierung von TRAILR1 oder TRAILR2 durch scFv:CD70-TRAIL-Mutanten
Entwicklung CD40/DC-stimulierender rekombinanter Proteine mit Tumorantigen-restringierter Aktivität
Apoptoseregulation durch TNF im Multiplen Myelom
Development of Modified polylysine based antibody conjugated nanoparticles with tumor-restricted, FcγR-independent stimulatory activity by targeting Fn14
Molecular mode of action of TRAIL receptor agonists—common principles and their translational exploitation
Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
The importance of antibody isotype and idiotype in FcγR-dependent agonism induced by anti-CD40 antibodies
Development of self-adjusting cytokine neutralizer cells as a closed-loop delivery system of anti-inflammatory biologicals
Enhancement of Toll-like receptor3 (TLR3)-induced death signaling by TNF-like weak inducer of apoptosis (TWEAK)
CD40-restringierte Aktivierung der TRAIL-Todesrezeptoren durch bifunktionelle rekombinante Proteine
Generierung und Charakterisierung rekombinanter TNF-Liganden
Development of CD40-targeted bifunctional scFv-TRAIL fusion proteins that induce TRAILR1- and TRAILR2-specifc cell death and dendritic cells activation
CD70-abhängige und spezifische Aktivierung von TRAILR1 oder TRAILR2 durch scFv:CD70-TRAIL-Mutanten
Entwicklung CD40/DC-stimulierender rekombinanter Proteine mit Tumorantigen-restringierter Aktivität
Apoptoseregulation durch TNF im Multiplen Myelom
Development of Modified polylysine based antibody conjugated nanoparticles with tumor-restricted, FcγR-independent stimulatory activity by targeting Fn14
Molecular mode of action of TRAIL receptor agonists—common principles and their translational exploitation
Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
The importance of antibody isotype and idiotype in FcγR-dependent agonism induced by anti-CD40 antibodies
Development of self-adjusting cytokine neutralizer cells as a closed-loop delivery system of anti-inflammatory biologicals
Enhancement of Toll-like receptor3 (TLR3)-induced death signaling by TNF-like weak inducer of apoptosis (TWEAK)
CD40-restringierte Aktivierung der TRAIL-Todesrezeptoren durch bifunktionelle rekombinante Proteine
Generierung und Charakterisierung rekombinanter TNF-Liganden
Development of CD40-targeted bifunctional scFv-TRAIL fusion proteins that induce TRAILR1- and TRAILR2-specifc cell death and dendritic cells activation
CD70-abhängige und spezifische Aktivierung von TRAILR1 oder TRAILR2 durch scFv:CD70-TRAIL-Mutanten
Entwicklung CD40/DC-stimulierender rekombinanter Proteine mit Tumorantigen-restringierter Aktivität